Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin

Table 3 Correlation between the changes of LDL-C subspecies, HDL-C subspecies and the changes of clinical parameters

	ΔHDL-C (mg/dL)		ΔHDL2-C (mg/dL)		ΔHDL3-C (mg/dL)		ΔHDL-C (mg/dL)		ΔHDL2-C (mg/dL)		ΔHDL3-C (mg/dL)
	r	p	r	p	r	p	r	p	r	p	r	p
ΔBW (kg)	−0.189	0.247	−0.208	0.203	0.002	0.986	0.107	0.509	−0.098	0.545	−0.221	0.169
ΔHbA1c (%)	−0.046	0.780	−0.073	0.656	0.036	0.826	0.263	0.109	0.329	0.043*	0.148	0.378
ΔC-peptide (ng/mL)	−0.074	0.671	−0.165	0.342	0.127	0.463	0.095	0.698	0.255	0.291	−0.300	0.211
ΔAST (IU/L)	0.220	0.178	0.220	0.177	0.029	0.860	−0.394	0.062	−0.347	0.104	0.072	0.742
ΔALT (IU/L)	0.164	0.316	0.168	0.306	0.017	0.915	−0.289	0.180	−0.263	0.225	0.052	0.810
ΔγGTP (IU/L)	0.197	0.227	0.153	0.350	0.095	0.563	0.201	0.570	−0.180	0.395	0.222	0.308

r coefficient of correlation, BW body weight, AST aspartate aminotransferase, ALT alanine aminotransferase, γGTP γ-glutamyltranspeptidase, LDL-C low-density lipoprotein-cholesterol, sd LDL-C small dense LDL-cholesterol, lb LDL-C large buoyant LDL-cholesterol, HDL-C high-density lipoprotein-cholesterol, HDL2-C high-density lipoprotein 2-cholesterol, HDL3-C high-density lipoprotein 3-cholesterol
* p < 0.05

ISSN: 1475-2840